Johnson Financial Group Inc. Sells 1,736 Shares of Bristol Myers Squibb Company $BMY

Johnson Financial Group Inc. lowered its position in Bristol Myers Squibb Company (NYSE:BMY) by 9.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,466 shares of the biopharmaceutical company’s stock after selling 1,736 shares during the period. Johnson Financial Group Inc.’s holdings in Bristol Myers Squibb were worth $762,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Brighton Jones LLC lifted its position in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares in the last quarter. Foundations Investment Advisors LLC lifted its position in shares of Bristol Myers Squibb by 9.3% during the first quarter. Foundations Investment Advisors LLC now owns 16,781 shares of the biopharmaceutical company’s stock worth $1,023,000 after purchasing an additional 1,429 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new position in shares of Bristol Myers Squibb during the first quarter worth approximately $113,000. Mesirow Financial Investment Management Inc. grew its stake in shares of Bristol Myers Squibb by 16.7% during the first quarter. Mesirow Financial Investment Management Inc. now owns 45,545 shares of the biopharmaceutical company’s stock valued at $2,778,000 after purchasing an additional 6,526 shares during the last quarter. Finally, SlateStone Wealth LLC increased its holdings in shares of Bristol Myers Squibb by 23.0% in the first quarter. SlateStone Wealth LLC now owns 4,815 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 900 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Up 0.6%

NYSE:BMY opened at $49.33 on Friday. The firm has a market capitalization of $100.43 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The business’s 50-day moving average price is $45.51 and its two-hundred day moving average price is $46.62. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same period last year, the company posted $1.80 EPS. Bristol Myers Squibb’s revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.0%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 83.78%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Citigroup reduced their price objective on Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating on the stock in a report on Monday, November 17th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Four analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $54.42.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.